News & Analysis as of July 24, 2025

Life Sciences

+ Follow

Antitrust Insights for Private Equity Navigating the New Administration's Policies — PE Pathways Podcast
The USDOJ Antitrust Division’s Compliance Guidance
Episode 341 -- DOJ Charges Visa with Monopolization and Exclusionary Conduct in the Debit Card Market
Podcast: Key Changes in Finalized Antitrust Merger Guidelines – Diagnosing Health Care
The Changing Landscape of State AG Antitrust Enforcement — Regulatory Oversight Podcast
Podcast - The Latest on Antitrust and Non-Compete Agreements in Healthcare
AGG Talks: Antitrust and White-Collar Crime Roundup - Inside the World of No-Poach Investigations and Indictments
The Latest from the DOJ Antitrust Division
Everything Compliance - The Elon Etc Edition
The Latest on Antitrust Compliance
Episode 219 -- DOJ Indicts Six Aerospace Executives for Restraining Competition in Labor Market
Nota Bene Podcast Episode 134: U.S. Q3 Check In: Infrastructure Bill Updates and Big Tech Antitrust with Elizabeth Frazee and Chani Wiggins
Healthcare Antitrust Enforcement Outlook with Former DOJ Antitrust Prosecutor and Strike Force District Leader
What to Expect from the Biden Administration
Compliance Perspectives: The Antitrust Division’s Office of Decree Enforcement
Nota Bene Episode 68: The Current Antitrust Enforcement Climate in the United States with Capitol Forum Senior Editor Nate Soderstrom
Employment Law This Week®: Employee Mobility

Healthcare & Antitrust: What to Expect in the New Trump Administration

WilmerHale on 5/27/2025

Antitrust scrutiny of healthcare markets is nothing new. The Biden Administration and first Trump Administration focused antitrust enforcement efforts across the healthcare and life sciences industries. The newly installed...more

What Are the Top Hatch-Waxman and BPCIA Developments for December 2018?

Morrison & Foerster LLP on 1/9/2019

This month we highlight two Federal Circuit obviousness-type double patenting decisions. CASES - Federal Circuit - Section 156 Patent Term Extension and Obviousness-Type Double Patenting - Novartis AG v. Ezra...more

2 Results

View per page

Page: of 1

Antitrust Division › Pharmaceutical Patents › Life Sciences

Healthcare & Antitrust: What to Expect in the New Trump Administration

What Are the Top Hatch-Waxman and BPCIA Developments for December 2018?

"My best business intelligence, in one easy email…"